Vivoscript Inc is a biotechnology company commercializing regenerative medicine. The firm's primary product is a technology platform is called In Vivo Cell Reprogramming, which uses a combination of protein drugs to convert one type of cell to another type of cell within a pateint's body. One application of the technology is liver cells being converted into beta cells to treat diabetes. The disease areas being focused on are diabetes, autoimmune diseases, and stroke.
